Just some weekend reading
Biotech Valuation Idiosyncrasies and Best Practices
Biotech companies with little to no revenue can still be worth billions. Consider the most prominent 2017 biotech M&A deal when Gilead bought Kite Pharma for almost $12 billion. At the time of the deal, Kite had over $600 million in accumulated deficit, but it also had a pipeline of CAR-T cell therapies, which treat cancer
https://www.toptal.com/finance/valuation/biotech-valuation
Industry news, page-1513
-
- There are more pages in this discussion • 345 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
-0.170(11.1%) |
Mkt cap ! $232.5M | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.48 | $1.36 | $632.2K | 451.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 76 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 4136 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |